BIOLASE (NASDAQ:BIOL) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL) in a note issued to investors on Monday. The brokerage set a “sell” rating on the medical technology company’s stock.

BIOL has been the subject of a number of other reports. Ascendiant Capital Markets cut their target price on BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. Benchmark restated a “speculative buy” rating and issued a $0.40 price objective on shares of BIOLASE in a report on Wednesday, October 2nd.

BIOLASE Price Performance

BIOL opened at $0.01 on Monday. The stock’s 50 day moving average price is $0.01 and its 200 day moving average price is $0.04. The stock has a market cap of $367,477.00, a P/E ratio of 0.00 and a beta of 0.67. BIOLASE has a 12 month low of $0.02 and a 12 month high of $1.94.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.